However, during a treatment, a patient with HER2-positive advanced GC developed severe upper gastrointestinal bleeding, suggesting that HER2-targeted CAR-T cell therapy may carry certain risks during the anti-tumor process. Here, ERBB2 is linked to neoplasm.